181039-93-0

Basic information

• Product Name: 4-(1,3-Benzodioxol-5-ylmethoxy)-2-hydroxybenzonitrile
• Synonyms: 4-(1,3-Benzodioxol-5-ylmethoxy)-2-hydroxybenzonitrile
• CAS NO: 181039-93-0
• Molecular Weight: 269.257
• Mol File: 181039-93-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 4-(1,3-Benzodioxol-5-ylmethoxy)-2-hydroxybenzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(1,3-Benzodioxol-5-ylmethoxy)-2-hydroxybenzonitrile(181039-93-0)
• EPA Substance Registry System: 4-(1,3-Benzodioxol-5-ylmethoxy)-2-hydroxybenzonitrile(181039-93-0)

Safety Data

• Hazardous Substances Data: 181039-93-0(Hazardous Substances Data)

Upstream product

• 181039-91-8 2-Acetoxy-4-(1,3-benzodioxol-5-ylmethoxy)benzonitrile 
• 181039-87-2 4-(1,3-Benzodioxol-5-ylmethoxy)-2-hydroxybenzaldehyde 
• 2950-43-8 hydroxylamine-O-sulfonic acid 
• 20850-43-5 5-(chloromethyl)-1,3-benzodioxole 
• 64419-24-5 2,4-dihydroxybenzonitrile 
• 95-01-2 2,4-Dihydroxybenzaldehyde 
• 495-76-1 piperonol 
• 5399-68-8 2,4-dihydroxyphenylaldoxime 
• 120-57-0 piperonal 
• 197571-05-4 4-cyano-1,3-phenylene diacetate 

Downstream Products

• 181040-01-7 methyl (RS)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyanophenoxy]-(2-trifluoromethylphenyl)acetate 
• 181040-08-4 methyl (RS)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyanophenoxy]-(2-chlorophenyl)acetate 
• 181039-95-2 Methyl (RS)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyano-phenoxy]-phenylacetate 

Relevant articles and documents

Discovery of phenoxybutanoic acid derivatives as potent endothelin antagonists with antihypertensive activity

A series of phenoxybutanoic acid derivatives were synthesized and tested for their antagonistic activity on the contraction of the rat thoracic aortic ring induced by endothelin-1. Preliminary screening results showed that 6e and 6g with benzoheterocycles demonstrated significant antagonistic activities when compared to the reference compound BQ123. The results from additional assays for the binding affinity and selectivity for endothelin receptors showed that 6e was a selective ETA antagonist with a nanomolar IC50. Moreover, 6e was effective in relieving hypoxia-induced pulmonary arterial hypertension and right ventricular weight ratio. Therefore, 6e may have potential for further development as a therapeutic agent for the treatment of cardiovascular diseases.

SUBSTITUTED PHENYL COMPOUNDS WITH A SUBSTITUENT HAVING A 1,3-BENZODIOXOLE RING

This invention is directed to compounds of formula I STR1 wherein R 1 is CN, CH 2 CN, CH=CHCN, CHO, or CH=CHCO. sub. 2 H;R 2 is aryl lower alkoxy, heteroaryl lower alkoxy, aryl lower alkylthio or heteroaryl lower alkylthio wherein each of the aryl and heteroaryl moieties is optionally substituted;R 3 is halogen;R 4 is optionally substituted aryl or optionally substituted heteroaryl;R. sup.5 is carboxy or an acid isostere; X is oxygen or sulphur; and n is zero or 1; or an N-oxide thereof, prodrug thereof solvate thereof, or pharmaceutically acceptable salt thereof, which compounds have endothelin antagonist activity. The invention is also directed to methods for preparing the compounds of formula I and their pharmaceutical use.